# THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)

> **NCT02002325** · PHASE3 · UNKNOWN · sponsor: **National Cerebral and Cardiovascular Center, Japan** · enrollment: 300 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Tissue-type plasminogen activator (alteplase)
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT02002325
- **Lead sponsor:** National Cerebral and Cardiovascular Center, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2019-12
- **Final completion:** 2020-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002325, "THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02002325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*